JP6234465B2 - Collagen fiber bundling ability enhancer - Google Patents
Collagen fiber bundling ability enhancer Download PDFInfo
- Publication number
- JP6234465B2 JP6234465B2 JP2015534177A JP2015534177A JP6234465B2 JP 6234465 B2 JP6234465 B2 JP 6234465B2 JP 2015534177 A JP2015534177 A JP 2015534177A JP 2015534177 A JP2015534177 A JP 2015534177A JP 6234465 B2 JP6234465 B2 JP 6234465B2
- Authority
- JP
- Japan
- Prior art keywords
- collagen
- tissue
- acid
- collagen fiber
- enhancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000008186 Collagen Human genes 0.000 title claims description 97
- 108010035532 Collagen Proteins 0.000 title claims description 97
- 229920001436 collagen Polymers 0.000 title claims description 97
- 239000000835 fiber Substances 0.000 title claims description 52
- 239000003623 enhancer Substances 0.000 title claims description 40
- 210000001519 tissue Anatomy 0.000 claims description 66
- 238000004519 manufacturing process Methods 0.000 claims description 36
- 210000003491 skin Anatomy 0.000 claims description 28
- 108090000738 Decorin Proteins 0.000 claims description 25
- 102000004237 Decorin Human genes 0.000 claims description 24
- 102000016611 Proteoglycans Human genes 0.000 claims description 23
- 108010067787 Proteoglycans Proteins 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 16
- 241000186012 Bifidobacterium breve Species 0.000 claims description 14
- 210000000845 cartilage Anatomy 0.000 claims description 12
- 239000000839 emulsion Substances 0.000 claims description 11
- 210000003041 ligament Anatomy 0.000 claims description 11
- 210000002435 tendon Anatomy 0.000 claims description 11
- 230000003239 periodontal effect Effects 0.000 claims description 10
- 239000006071 cream Substances 0.000 claims description 8
- 230000001737 promoting effect Effects 0.000 claims description 8
- 235000013322 soy milk Nutrition 0.000 claims description 8
- 102100036411 Dermatopontin Human genes 0.000 claims description 7
- 101710088341 Dermatopontin Proteins 0.000 claims description 7
- 230000002708 enhancing effect Effects 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 210000004204 blood vessel Anatomy 0.000 claims description 4
- 210000004207 dermis Anatomy 0.000 claims description 4
- 230000009467 reduction Effects 0.000 claims description 4
- 230000008439 repair process Effects 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 3
- 239000002473 artificial blood Substances 0.000 claims description 2
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 239000000047 product Substances 0.000 description 57
- 238000000855 fermentation Methods 0.000 description 47
- 230000004151 fermentation Effects 0.000 description 47
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 28
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 25
- -1 polyoxyethylene Polymers 0.000 description 20
- 241000186000 Bifidobacterium Species 0.000 description 19
- 241000894006 Bacteria Species 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- 244000005700 microbiome Species 0.000 description 16
- 239000002994 raw material Substances 0.000 description 16
- 239000002609 medium Substances 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 15
- 239000004310 lactic acid Substances 0.000 description 14
- 235000014655 lactic acid Nutrition 0.000 description 14
- 235000010323 ascorbic acid Nutrition 0.000 description 13
- 239000011668 ascorbic acid Substances 0.000 description 13
- 229960005070 ascorbic acid Drugs 0.000 description 13
- 230000014509 gene expression Effects 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 12
- 244000046052 Phaseolus vulgaris Species 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 239000000284 extract Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 239000006096 absorbing agent Substances 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 230000007423 decrease Effects 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 229940069765 bean extract Drugs 0.000 description 5
- 239000002537 cosmetic Substances 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 229930182478 glucoside Natural products 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 239000006210 lotion Substances 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000001172 regenerating effect Effects 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- 229940058015 1,3-butylene glycol Drugs 0.000 description 3
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- 229920002907 Guar gum Polymers 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 239000004166 Lanolin Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 235000019437 butane-1,3-diol Nutrition 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 235000015165 citric acid Nutrition 0.000 description 3
- 230000037319 collagen production Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 235000010417 guar gum Nutrition 0.000 description 3
- 239000000665 guar gum Substances 0.000 description 3
- 229960002154 guar gum Drugs 0.000 description 3
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 3
- 229940039717 lanolin Drugs 0.000 description 3
- 235000019388 lanolin Nutrition 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- 208000028169 periodontal disease Diseases 0.000 description 3
- 239000002861 polymer material Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 229930182490 saponin Natural products 0.000 description 3
- 235000017709 saponins Nutrition 0.000 description 3
- 150000007949 saponins Chemical class 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- 241001116389 Aloe Species 0.000 description 2
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 2
- 240000006891 Artemisia vulgaris Species 0.000 description 2
- 241001474374 Blennius Species 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 101001000206 Homo sapiens Decorin Proteins 0.000 description 2
- 101000929047 Homo sapiens Dermatopontin Proteins 0.000 description 2
- 101000860430 Homo sapiens Versican core protein Proteins 0.000 description 2
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 2
- 244000280244 Luffa acutangula Species 0.000 description 2
- 235000009814 Luffa aegyptiaca Nutrition 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 241000736199 Paeonia Species 0.000 description 2
- 235000006484 Paeonia officinalis Nutrition 0.000 description 2
- 241000218657 Picea Species 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 241000235527 Rhizopus Species 0.000 description 2
- 241000235070 Saccharomyces Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 235000007303 Thymus vulgaris Nutrition 0.000 description 2
- 240000002657 Thymus vulgaris Species 0.000 description 2
- TUYRNAGGIJZRNM-LBHUVFDKSA-N [(2s)-2-[(2r)-4-hexadecanoyloxy-3-hydroxy-5-oxo-2h-furan-2-yl]-2-hydroxyethyl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(OC(=O)CCCCCCCCCCCCCCC)=C1O TUYRNAGGIJZRNM-LBHUVFDKSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 235000011399 aloe vera Nutrition 0.000 description 2
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 2
- 235000020244 animal milk Nutrition 0.000 description 2
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 238000003287 bathing Methods 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- KVYGGMBOZFWZBQ-UHFFFAOYSA-N benzyl nicotinate Chemical compound C=1C=CN=CC=1C(=O)OCC1=CC=CC=C1 KVYGGMBOZFWZBQ-UHFFFAOYSA-N 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 235000020251 goat milk Nutrition 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 102000045840 human DCN Human genes 0.000 description 2
- 102000050465 human DPT Human genes 0.000 description 2
- 102000043769 human VCAN Human genes 0.000 description 2
- 235000020256 human milk Nutrition 0.000 description 2
- 210000004251 human milk Anatomy 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 2
- 235000010449 maltitol Nutrition 0.000 description 2
- 239000000845 maltitol Substances 0.000 description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 2
- 229940035436 maltitol Drugs 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000020712 soy bean extract Nutrition 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- 239000001585 thymus vulgaris Substances 0.000 description 2
- LOIYMIARKYCTBW-UHFFFAOYSA-N trans-urocanic acid Natural products OC(=O)C=CC1=CNC=N1 LOIYMIARKYCTBW-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 229930007845 β-thujaplicin Natural products 0.000 description 2
- WGVKWNUPNGFDFJ-DQCZWYHMSA-N β-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C WGVKWNUPNGFDFJ-DQCZWYHMSA-N 0.000 description 2
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 1
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 1
- FPJHWYCPAOPVIV-VOZMEZHOSA-N (2R,3S,4R,5R,6R)-6-[(2R,3R,4R,5R,6R)-5-acetamido-2-(hydroxymethyl)-6-methoxy-3-sulfooxyoxan-4-yl]oxy-4,5-dihydroxy-3-methoxyoxane-2-carboxylic acid Chemical compound CO[C@@H]1O[C@H](CO)[C@H](OS(O)(=O)=O)[C@H](O[C@@H]2O[C@H]([C@@H](OC)[C@H](O)[C@H]2O)C(O)=O)[C@H]1NC(C)=O FPJHWYCPAOPVIV-VOZMEZHOSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- MRAMPOPITCOOIN-VIFPVBQESA-N (2r)-n-(3-ethoxypropyl)-2,4-dihydroxy-3,3-dimethylbutanamide Chemical compound CCOCCCNC(=O)[C@H](O)C(C)(C)CO MRAMPOPITCOOIN-VIFPVBQESA-N 0.000 description 1
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- CWLGEPSKQDNHIO-JOBJLJCHSA-N (e)-n-[(e)-benzylideneamino]-1-phenylmethanimine Chemical compound C=1C=CC=CC=1/C=N/N=C/C1=CC=CC=C1 CWLGEPSKQDNHIO-JOBJLJCHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- MUHFRORXWCGZGE-KTKRTIGZSA-N 2-hydroxyethyl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCO MUHFRORXWCGZGE-KTKRTIGZSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- GECRRQVLQHRVNH-MRCUWXFGSA-N 2-octyldodecyl (z)-octadec-9-enoate Chemical compound CCCCCCCCCCC(CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC GECRRQVLQHRVNH-MRCUWXFGSA-N 0.000 description 1
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- MSPJNHHBNOLHOC-UHFFFAOYSA-N 3,3-dimethylcyclopropane-1,2-dicarboxylic acid Chemical compound CC1(C)C(C(O)=O)C1C(O)=O MSPJNHHBNOLHOC-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- RDBLNMQDEWOUIB-UHFFFAOYSA-N 5-methyl-2-phenyl-1,3-benzoxazole Chemical compound N=1C2=CC(C)=CC=C2OC=1C1=CC=CC=C1 RDBLNMQDEWOUIB-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 241000589220 Acetobacter Species 0.000 description 1
- 240000000073 Achillea millefolium Species 0.000 description 1
- 235000007754 Achillea millefolium Nutrition 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000584629 Aosa Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000086254 Arnica montana Species 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 1
- 235000007689 Borago officinalis Nutrition 0.000 description 1
- 240000004355 Borago officinalis Species 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 235000014653 Carica parviflora Nutrition 0.000 description 1
- 244000132059 Carica parviflora Species 0.000 description 1
- 241001107116 Castanospermum australe Species 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 241000422842 Chamaecyparis pisifera Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 241000195628 Chlorophyta Species 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 1
- 235000009685 Crataegus X maligna Nutrition 0.000 description 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 1
- 235000009486 Crataegus bullatus Nutrition 0.000 description 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 1
- 235000009682 Crataegus limnophila Nutrition 0.000 description 1
- 240000000171 Crataegus monogyna Species 0.000 description 1
- 235000004423 Crataegus monogyna Nutrition 0.000 description 1
- 235000002313 Crataegus paludosa Nutrition 0.000 description 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 1
- 239000001879 Curdlan Substances 0.000 description 1
- 229920002558 Curdlan Polymers 0.000 description 1
- 241000192700 Cyanobacteria Species 0.000 description 1
- 235000017788 Cydonia oblonga Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000195955 Equisetum hyemale Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 240000001972 Gardenia jasminoides Species 0.000 description 1
- 241000589236 Gluconobacter Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 229920000288 Keratan sulfate Polymers 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 231100000960 LabCyte EPI-MODEL 24 Toxicity 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241000194036 Lactococcus Species 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 241000234435 Lilium Species 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 235000018330 Macadamia integrifolia Nutrition 0.000 description 1
- 235000003800 Macadamia tetraphylla Nutrition 0.000 description 1
- 240000000912 Macadamia tetraphylla Species 0.000 description 1
- 240000000982 Malva neglecta Species 0.000 description 1
- 235000000060 Malva neglecta Nutrition 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241000228347 Monascus <ascomycete fungus> Species 0.000 description 1
- 241000235395 Mucor Species 0.000 description 1
- AOMUHOFOVNGZAN-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)dodecanamide Chemical compound CCCCCCCCCCCC(=O)N(CCO)CCO AOMUHOFOVNGZAN-UHFFFAOYSA-N 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 241000221960 Neurospora Species 0.000 description 1
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 1
- RJECHNNFRHZQKU-UHFFFAOYSA-N Oelsaeurecholesterylester Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCC=CCCCCCCCC)C2 RJECHNNFRHZQKU-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 241000206755 Palmaria Species 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- DJWYOLJPSHDSAL-UHFFFAOYSA-N Pantethine Natural products OCC(C)(C)C(O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)C(O)C(C)(C)CO DJWYOLJPSHDSAL-UHFFFAOYSA-N 0.000 description 1
- 241000237503 Pectinidae Species 0.000 description 1
- 241000192001 Pediococcus Species 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- ALQSHHUCVQOPAS-UHFFFAOYSA-N Pentane-1,5-diol Chemical class OCCCCCO ALQSHHUCVQOPAS-UHFFFAOYSA-N 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 235000016311 Primula vulgaris Nutrition 0.000 description 1
- 244000028344 Primula vulgaris Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 241000206572 Rhodophyta Species 0.000 description 1
- 241000223252 Rhodotorula Species 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- YDBYJHTYSHBBAU-YFKPBYRVSA-N S-methyl-L-methioninate Chemical compound C[S+](C)CC[C@H](N)C([O-])=O YDBYJHTYSHBBAU-YFKPBYRVSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- KYWSCMDFVARMPN-LCSVLAELSA-N Saikosaponin D Chemical compound O([C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@]([C@H]3[C@]([C@@H]4[C@@]([C@@]5(C[C@@H](O)[C@]67CO[C@]5([C@@H]6CC(C)(C)CC7)C=C4)C)(C)CC3)(C)CC2)(C)CO)O[C@@H]([C@@H]1O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O KYWSCMDFVARMPN-LCSVLAELSA-N 0.000 description 1
- 235000002953 Saxifraga stolonifera Nutrition 0.000 description 1
- 244000288377 Saxifraga stolonifera Species 0.000 description 1
- 241000235346 Schizosaccharomyces Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- VBIIFPGSPJYLRR-UHFFFAOYSA-M Stearyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)C VBIIFPGSPJYLRR-UHFFFAOYSA-M 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 241000006364 Torula Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 108010077465 Tropocollagen Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 241001261506 Undaria pinnatifida Species 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 244000090207 Vigna sesquipedalis Species 0.000 description 1
- 235000005072 Vigna sesquipedalis Nutrition 0.000 description 1
- 235000011453 Vigna umbellata Nutrition 0.000 description 1
- 240000001417 Vigna umbellata Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003756 Vitamin B7 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 229920002000 Xyloglucan Polymers 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- UDRYFKCHZFVZGJ-UHFFFAOYSA-N [5-hexadecanoyloxy-4-(hexadecanoyloxymethyl)-6-methylpyridin-3-yl]methyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC1=CN=C(C)C(OC(=O)CCCCCCCCCCCCCCC)=C1COC(=O)CCCCCCCCCCCCCCC UDRYFKCHZFVZGJ-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- QPMSXSBEVQLBIL-CZRHPSIPSA-N ac1mix0p Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1.O([C@H]1[C@]2(OC)C=CC34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O QPMSXSBEVQLBIL-CZRHPSIPSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- LFYJSSARVMHQJB-QIXNEVBVSA-N bakuchiol Chemical compound CC(C)=CCC[C@@](C)(C=C)\C=C\C1=CC=C(O)C=C1 LFYJSSARVMHQJB-QIXNEVBVSA-N 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 229950004580 benzyl nicotinate Drugs 0.000 description 1
- 229940066595 beta tocopherol Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229940004120 bifidobacterium infantis Drugs 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- ZCLVNIZJEKLGFA-UHFFFAOYSA-H bis(4,5-dioxo-1,3,2-dioxalumolan-2-yl) oxalate Chemical compound [Al+3].[Al+3].[O-]C(=O)C([O-])=O.[O-]C(=O)C([O-])=O.[O-]C(=O)C([O-])=O ZCLVNIZJEKLGFA-UHFFFAOYSA-H 0.000 description 1
- 229940036350 bisabolol Drugs 0.000 description 1
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 description 1
- 235000021279 black bean Nutrition 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 235000010338 boric acid Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 239000004204 candelilla wax Substances 0.000 description 1
- 235000013868 candelilla wax Nutrition 0.000 description 1
- 229940073532 candelilla wax Drugs 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 229940082483 carnauba wax Drugs 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000012185 ceresin wax Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- RJECHNNFRHZQKU-RMUVNZEASA-N cholesteryl oleate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)C1 RJECHNNFRHZQKU-RMUVNZEASA-N 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 235000019316 curdlan Nutrition 0.000 description 1
- 229940078035 curdlan Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229940071120 dehydroacetate Drugs 0.000 description 1
- 239000000551 dentifrice Substances 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 229940051593 dermatan sulfate Drugs 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- YVIGPQSYEAOLAD-UHFFFAOYSA-L disodium;dodecyl phosphate Chemical compound [Na+].[Na+].CCCCCCCCCCCCOP([O-])([O-])=O YVIGPQSYEAOLAD-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- SYELZBGXAIXKHU-UHFFFAOYSA-N dodecyldimethylamine N-oxide Chemical compound CCCCCCCCCCCC[N+](C)(C)[O-] SYELZBGXAIXKHU-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- MCPKSFINULVDNX-UHFFFAOYSA-N drometrizole Chemical compound CC1=CC=C(O)C(N2N=C3C=CC=CC3=N2)=C1 MCPKSFINULVDNX-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- FODTZLFLDFKIQH-FSVGXZBPSA-N gamma-Oryzanol (TN) Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-FSVGXZBPSA-N 0.000 description 1
- 235000010382 gamma-tocopherol Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 201000005562 gingival recession Diseases 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000008169 grapeseed oil Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 1
- ACGUYXCXAPNIKK-UHFFFAOYSA-N hexachlorophene Chemical compound OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(O)C(Cl)=CC(Cl)=C1Cl ACGUYXCXAPNIKK-UHFFFAOYSA-N 0.000 description 1
- 229960004068 hexachlorophene Drugs 0.000 description 1
- SFFVATKALSIZGN-UHFFFAOYSA-N hexadecan-7-ol Chemical compound CCCCCCCCCC(O)CCCCCC SFFVATKALSIZGN-UHFFFAOYSA-N 0.000 description 1
- WYVGZXIHGGQSQN-UHFFFAOYSA-N hexadecanoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCCCCCCCCCC(O)=O WYVGZXIHGGQSQN-UHFFFAOYSA-N 0.000 description 1
- 229940005740 hexametaphosphate Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 235000014304 histidine Nutrition 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 229960004903 invert sugar Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N isopropyl alcohol Natural products CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 229940114937 microcrystalline wax Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 235000021278 navy bean Nutrition 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000010466 nut oil Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229960001679 octinoxate Drugs 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940073665 octyldodecyl myristate Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960005010 orotic acid Drugs 0.000 description 1
- 239000010330 ougon Substances 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 235000008975 pantethine Nutrition 0.000 description 1
- 239000011581 pantethine Substances 0.000 description 1
- DJWYOLJPSHDSAL-ROUUACIJSA-N pantethine Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO DJWYOLJPSHDSAL-ROUUACIJSA-N 0.000 description 1
- 229960000903 pantethine Drugs 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000019809 paraffin wax Nutrition 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 1
- 210000004261 periodontium Anatomy 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- MQOCIYICOGDBSG-UHFFFAOYSA-M potassium;hexadecanoate Chemical compound [K+].CCCCCCCCCCCCCCCC([O-])=O MQOCIYICOGDBSG-UHFFFAOYSA-M 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 239000001651 pyrus cydonia seed extract Substances 0.000 description 1
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 1
- 229960001755 resorcinol Drugs 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000007788 roughening Methods 0.000 description 1
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 229930192014 saikosaponin Natural products 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 235000020637 scallop Nutrition 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229940080236 sodium cetyl sulfate Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 229940045920 sodium pyrrolidone carboxylate Drugs 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- HYRLWUFWDYFEES-UHFFFAOYSA-M sodium;2-oxopyrrolidine-1-carboxylate Chemical compound [Na+].[O-]C(=O)N1CCCC1=O HYRLWUFWDYFEES-UHFFFAOYSA-M 0.000 description 1
- GGHPAKFFUZUEKL-UHFFFAOYSA-M sodium;hexadecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCCCOS([O-])(=O)=O GGHPAKFFUZUEKL-UHFFFAOYSA-M 0.000 description 1
- 229940075554 sorbate Drugs 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 1
- 239000001570 sorbitan monopalmitate Substances 0.000 description 1
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- LOIYMIARKYCTBW-OWOJBTEDSA-N trans-urocanic acid Chemical compound OC(=O)\C=C\C1=CNC=N1 LOIYMIARKYCTBW-OWOJBTEDSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000011912 vitamin B7 Nutrition 0.000 description 1
- 239000011735 vitamin B7 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 239000009538 yokuinin Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 235000007680 β-tocopherol Nutrition 0.000 description 1
- 239000011590 β-tocopherol Substances 0.000 description 1
- 239000002478 γ-tocopherol Substances 0.000 description 1
- QUEDXNHFTDJVIY-DQCZWYHMSA-N γ-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-DQCZWYHMSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Birds (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Cosmetics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Materials For Medical Uses (AREA)
Description
本発明は、コラーゲン線維の結束能増強剤に関し、更に詳細には、ビフィドバクテリウム属細菌および/または乳酸菌から選ばれる微生物による発酵生成物を有効成分とする、コラーゲン線維の結束能増強剤およびその使用方法に関する。 The present invention relates to a collagen fiber bundling ability enhancer, and more specifically, a collagen fiber bundling ability enhancer comprising, as an active ingredient, a fermentation product of a microorganism selected from Bifidobacterium and / or lactic acid bacteria, and It relates to its usage.
ビフィドバクテリウム属細菌や乳酸菌中には、その発酵生成物中に有用な成分を産生するものが数多く知られている。 Many Bifidobacterium and lactic acid bacteria that produce useful components in their fermentation products are known.
例えば、本出願人は、ビフィドバクテリウム属細菌であるビフィドバクテリウム・ブレーベについて研究を行い、これで大豆抽出物を発酵させて得た発酵生成物が保湿作用を有し、保湿剤として有効であること(特許文献1)や、この発酵生成物とビタミンA類を組み合わせた皮膚外用剤は、細胞賦活効果やヒアルロン酸産生効果を有し、肌荒れ防止・改善剤として有用であること(特許文献2)を見出した。更に前記発酵生成物を更に有機溶媒抽出して得た組成物は、より高い肌荒れ防止効果および皮膚老化防止効果を有すること(特許文献3)等も見出し、報告している。 For example, the present applicant has studied Bifidobacterium breve, which is a bacterium belonging to the genus Bifidobacterium, and the fermentation product obtained by fermenting the soybean extract has a moisturizing action and serves as a moisturizing agent. It is effective (patent document 1), and the skin external preparation which combined this fermentation product and vitamin A has a cell activation effect and a hyaluronic acid production effect, and is useful as a rough skin prevention and improvement agent ( Patent Document 2) was found. Furthermore, it has also been found and reported that a composition obtained by further extracting the fermentation product with an organic solvent has a higher skin roughening prevention effect and a skin aging prevention effect (Patent Document 3).
それ以外にも、豆乳にリゾープス属の微生物を作用させたもの(特許文献4)、乳酸菌を作用させたもの(特許文献5)等、いわゆる発酵生成物の機能性を化粧料等に利用することも知られている。 Other than that, use the functionality of so-called fermentation products for cosmetics and the like, such as those obtained by allowing Rhizopus microorganisms to act on soy milk (Patent Document 4), those causing lactic acid bacteria to act (Patent Document 5), etc. Is also known.
このように、ビフィドバクテリウム属や、他の細菌等の微生物の発酵生成物が種々の機能性を有することが見出されているが、更に、これら発酵生成物から今までに知られていない機能性を新たに見出すことも期待されている。 As described above, it has been found that fermentation products of microorganisms such as Bifidobacterium and other bacteria have various functions. Further, these fermentation products have been known so far. It is also expected to find new functionality.
従って、本発明は、ビフィドバクテリウム属細菌や乳酸菌を用いた発酵生成物の有する新規な機能性を見出し、これを利用する製剤やその使用方法の提供をその課題とするものである。 Accordingly, an object of the present invention is to find a novel functionality possessed by a fermentation product using a Bifidobacterium genus bacterium or a lactic acid bacterium, and to provide a preparation using the same and a method for using the same.
本発明者らは、ビフィドバクテリウム属細菌や乳酸菌を用いた発酵生成物の機能性についてその研究を更に進めていたところ、このものはコラーゲン線維束の形成に不可欠な特定のプロテオグリカンの量を増やす効果を有し、コラーゲン線維の結束能増強剤として有効であることを見出し、本発明を完成した。 The present inventors have further advanced the research on the functionality of fermentation products using Bifidobacterium and lactic acid bacteria, and this is the amount of specific proteoglycans essential for the formation of collagen fiber bundles. The present invention was completed by finding that it has an effect of increasing and is effective as an agent for enhancing the binding ability of collagen fibers.
すなわち本発明は、ビフィドバクテリウム属細菌および/または乳酸菌から選ばれる微生物による発酵生成物を有効成分とするコラーゲン線維の結束能増強剤である。 That is, the present invention is a collagen fiber bundling ability enhancer comprising a fermentation product of a microorganism selected from Bifidobacterium and / or lactic acid bacteria as an active ingredient.
また本発明は、コラーゲンを含む生体組織に、上記コラーゲン線維の結束能増強剤を投与することを特徴とするコラーゲンを含む生体組織の修復方法である。 The present invention also provides a method for repairing a biological tissue containing collagen, comprising administering the collagen fiber binding ability enhancer to the biological tissue containing collagen.
更に本発明は、コラーゲンを含む生体組織に、前記コラーゲン線維の結束能増強剤を投与することを特徴とするコラーゲンを含む生体組織の強度低下予防方法である。 Furthermore, the present invention is a method for preventing a decrease in strength of a biological tissue containing collagen, comprising administering the collagen fiber binding ability enhancer to the biological tissue containing collagen.
また更に本発明は、コラーゲン組織を利用する再生組織の培養中または組織欠損部分への適用時において、前記コラーゲン線維の結束能増強剤を添加使用することを特徴とする再生組織の強度増強方法である。 Furthermore, the present invention relates to a method for enhancing the strength of a regenerated tissue, characterized in that the collagen fiber binding ability enhancer is added and used during culture of regenerated tissue using collagen tissue or when applied to a tissue defect part. is there.
本発明のコラーゲン線維の結束能増強剤の有効成分として使用されるビフィドバクテリウム属細菌や乳酸菌による発酵生成物は、特定のプロテオグリカンの産生量を増やすことで、コラーゲン線維束の形成を促進させて組織強度を増強させる効果を持ち、且つ、安全性の高いものである。 Fermentation products by Bifidobacterium and lactic acid bacteria used as active ingredients of the collagen fiber binding ability enhancer of the present invention promote the formation of collagen fiber bundles by increasing the production of specific proteoglycans. It has the effect of enhancing the tissue strength and is highly safe.
従って、本発明のコラーゲン線維の結束能増強剤は、事故、疾病等により強度が低下した、靭帯、腱、軟骨、皮膚、歯周組織等の生体組織に使用し、正常なコラーゲン組織に修復することができるものである。また、強度の低下が懸念されるコラーゲンを含む生体組織に予め使用し、その強度低下を予防することもできる。更に、近年注目されている再生医療のために人工的に作られる組織の強度を上げるためなどにも用いることができる。 Therefore, the collagen fiber bundling ability enhancer of the present invention is used for biological tissues such as ligaments, tendons, cartilage, skin, and periodontal tissues whose strength has been reduced due to accidents, illnesses, etc., and restored to normal collagen tissues. It is something that can be done. In addition, it can be used in advance for a biological tissue containing collagen, which is concerned about a decrease in strength, and the decrease in strength can be prevented. Furthermore, it can also be used to increase the strength of tissue that is artificially created for regenerative medicine, which has been attracting attention in recent years.
本発明において、「コラーゲン線維の結束能増強剤」とは、コラーゲン線維を束ねて、コラーゲン線維束の形成を促す作用を示す製剤を意味する。特に、コラーゲン線維を束ねる役割を果たし、コラーゲン線維束の形成に不可欠なプロテオグリカンの産生促進作用を示す製剤をさす。なお、ここでいうコラーゲン線維とは、α鎖とよばれるコラーゲン様配列をもつポリペプチド鎖が3本より合わさったらせん構造(以下、トロポコラーゲンという)が1つ以上集まったものをさし、コラーゲン線維中のトロポコラーゲンの数は特に限定されない。この製剤は、特に靭帯、腱、軟骨、皮膚、歯周組織から選ばれる生体組織の修復、あるいは靭帯、腱、軟骨、皮膚、歯周組織から選ばれる生体組織の強度低下の予防に用いられるものである。 In the present invention, the “collagen fiber binding ability enhancer” means a preparation that has an action of binding collagen fibers and promoting the formation of collagen fiber bundles. In particular, it refers to a preparation that plays a role in bundling collagen fibers and exhibits a proteoglycan production promoting action essential for the formation of collagen fiber bundles. The collagen fiber here refers to a collection of one or more spiral structures (hereinafter referred to as tropocollagen) in which three polypeptide chains having a collagen-like sequence called α chain are combined, The number of tropocollagens in the collagen fibers is not particularly limited. This preparation is particularly used for the repair of biological tissue selected from ligaments, tendons, cartilage, skin, and periodontal tissues, or the prevention of reduced strength of biological tissues selected from ligaments, tendons, cartilage, skin, and periodontal tissues. It is.
すなわち、コラーゲンは血管、靭帯、腱、骨、軟骨、歯周組織、皮膚といった結合組織に多量に存在しているタンパク質で細胞間マトリックスの主成分であり、近接する細胞の足場として、細胞の増殖および情報伝達に関与している。そして、この結合組織内においては、コラーゲンは主にコラーゲン線維束と呼ばれるコラーゲンの線維が寄り集まった構造体を形成しており、コラーゲン線維がプロテオグリカンやエラスチンにより強固に束ねられて、かつ規則正しく配列していることにより、組織に適度な強度が与えられている。 That is, collagen is a protein that is present in large amounts in connective tissues such as blood vessels, ligaments, tendons, bones, cartilage, periodontal tissue, and skin, and is the main component of the intercellular matrix, and as a scaffold for adjacent cells, cell proliferation And is involved in communication. In this connective tissue, collagen mainly forms a structure of collagen fibers called collagen fiber bundles. The collagen fibers are tightly bundled by proteoglycan and elastin and regularly arranged. Therefore, an appropriate strength is given to the tissue.
逆に、事故、疾病等何らかの理由で強固なコラーゲン線維束および配列が維持できなくなると、組織が正常な強度を保てず、また上記のような組織内の細胞の生理作用にも影響がでることが懸念される。 On the other hand, if a strong collagen fiber bundle and arrangement cannot be maintained for some reason such as an accident or disease, the tissue cannot maintain normal strength, and the physiological function of the cells in the tissue as described above is also affected. There is concern.
本発明のコラーゲン線維の結束能増強剤は、特定のプロテオグリカンの量を増やすことで、コラーゲン線維束の形成を促進させ、コラーゲン組織の強度低下を予防するものである。また、上記のようなコラーゲン線維束の形成や配列に問題が生じている場合に、特定のプロテオグリカンの産生を促進することで、コラーゲン線維束の形成を助け、結果として正常なコラーゲン組織に修復するものである。また、本発明のコラーゲン線維の結束能増強剤は、プロテオグリカンの中でも、特にデコリンおよび/またはデルマトポンチン産生促進作用を有することが好ましい。デコリンやデルマトポンチンは、特にコラーゲン線維束の作成に関与するプロテオグリカンであり、これらを特異的に増やすことにより、コラーゲン線維の結束能をより増強させることができる。一方、プロテオグリカンの1つであるバーシカンは、コラーゲン線維を束ねる働きをするエラスチンの生成を阻害することが知られている。よって、本発明のコラーゲン線維の結束能増強剤はバーシカンの産生を実質的に促進しない、あるいはその産生量を選択的に低減させるものであることが好ましい。なお、皮膚組織においては、真皮のみにコラーゲンが含まれるが、本発明のコラーゲン線維の結束能増強剤を使用することで表皮細胞においてもプロテオグリカン量が増加することが確認されている。一般的に、表皮中で発現したプロテオグリカンも真皮のコラーゲン線維の結束に関与することが知られていることから、本発明のコラーゲン線維の結束能増強剤は、皮膚組織全体に適用することができる。 The collagen fiber binding ability enhancer of the present invention increases the amount of a specific proteoglycan, thereby promoting the formation of collagen fiber bundles and preventing a decrease in the strength of the collagen tissue. Also, when there is a problem with the formation and arrangement of collagen fiber bundles as described above, it promotes the production of specific proteoglycans, thereby helping to form collagen fiber bundles and consequently restoring normal collagen tissue Is. The collagen fiber bundling ability enhancer of the present invention preferably has an action of promoting decorin and / or dermatopontin production, among proteoglycans. Decorin and dermatopontin are proteoglycans that are particularly involved in the production of collagen fiber bundles, and by specifically increasing these, the ability to bind collagen fibers can be further enhanced. On the other hand, versican, which is one of proteoglycans, is known to inhibit the production of elastin that functions to bundle collagen fibers. Therefore, it is preferable that the collagen fiber binding ability enhancer of the present invention does not substantially promote versican production or selectively reduces the production amount. In skin tissue, collagen is contained only in the dermis, and it has been confirmed that the amount of proteoglycan increases in epidermal cells by using the collagen fiber binding ability enhancer of the present invention. In general, it is known that proteoglycans expressed in the epidermis are also involved in the binding of collagen fibers in the dermis. Therefore, the collagen fiber binding ability enhancer of the present invention can be applied to the entire skin tissue. .
なお、本発明のコラーゲン線維の結束能増強効果は、コラーゲン産生促進作用とは全く異なる別の効果である。コラーゲン産生促進作用はコラーゲン自体の量を増加させるものであるが、特定のプロテオグリカンがなければコラーゲン線維束が形成されず、コラーゲン組織の強度を維持することができない。本願は、コラーゲン自体ではなく、特定のプロテオグリカンの量を増加させることにより、コラーゲン線維束の形成を促進させるものである。 The effect of enhancing the binding ability of the collagen fibers of the present invention is another effect that is completely different from the collagen production promoting action. Collagen production promoting action increases the amount of collagen itself, but without specific proteoglycans, collagen fiber bundles are not formed, and the strength of collagen tissue cannot be maintained. The present application promotes the formation of collagen fiber bundles by increasing the amount of specific proteoglycans, not collagen itself.
本発明のコラーゲン線維の結束能増強剤(以下、単に「コラーゲン増強剤」という)はビフィドバクテリウム属細菌および/または乳酸菌から選ばれる微生物による発酵生成物(以下、「発酵生成物」と略称する)を有効成分とするものである。ここでいう発酵生成物とは、ビフィドバクテリウム属細菌および/または乳酸菌によって発酵可能な原料を、これら微生物で発酵させて得られるものをいう。これら発酵生成物中には、ビフィドバクテリウム属細菌や乳酸菌の微生物菌体を含有していても、また含有していなくてもよく、これらの微生物菌体をろ過等により培養物から除去した上清等も本発明の発酵生成物中に包含される。 The collagen fiber bundling ability enhancer (hereinafter simply referred to as “collagen enhancer”) of the present invention is a fermentation product (hereinafter abbreviated as “fermentation product”) by a microorganism selected from Bifidobacterium and / or lactic acid bacteria. )) As an active ingredient. The fermentation product as used herein refers to a product obtained by fermenting a raw material that can be fermented by Bifidobacterium and / or lactic acid bacteria with these microorganisms. These fermentation products may or may not contain microbial cells of Bifidobacterium or lactic acid bacteria, and these microbial cells were removed from the culture by filtration or the like. Supernatant and the like are also included in the fermentation product of the present invention.
上記発酵生成物の原料として使用される培地としては、ビフィドバクテリウム属細菌および/または乳酸菌で発酵可能なものであれば特に限定されず、例えば、アロエ、豆類等の植物由来の原料や、牛乳、人乳、山羊乳等の獣乳、クリーム、脱脂粉乳等の動物由来の原料を含む培地が挙げられる。これらの原料は、ミキサー等による粉砕処理、抽出処理、ろ過や遠心分離処理、溶媒による溶解や希釈処理、酵素処理等を行ってもよい。また、これらの原料の中でも、牛乳、人乳、山羊乳等の獣乳、クリーム、脱脂粉乳等の乳成分を含有する培地または豆類抽出物を含有する培地を使用することが好ましく、豆類抽出物を含有する培地が特に好ましい。豆類としては、例えば大豆、黒豆、空豆、小豆、いんげん豆、えんどう豆、ひよこ豆等の豆類抽出物が挙げられるが、特に大豆抽出物が好ましい。 The medium used as a raw material for the fermentation product is not particularly limited as long as it can be fermented with Bifidobacterium and / or lactic acid bacteria, for example, plant-derived raw materials such as aloe, beans, Examples thereof include medium containing animal-derived raw materials such as animal milk such as cow's milk, human milk, goat milk, cream, and skim milk powder. These raw materials may be subjected to a pulverization process using a mixer or the like, an extraction process, a filtration or a centrifugal separation process, a dissolution or dilution process using a solvent, an enzyme process, or the like. Further, among these raw materials, it is preferable to use a medium containing milk components such as animal milk such as milk, human milk, goat milk, cream, skim milk powder, or a medium containing legume extract. A medium containing is particularly preferred. Examples of beans include bean extracts such as soybean, black bean, empty bean, red bean, kidney bean, pea bean, and chick bean, with soybean extract being particularly preferred.
上記豆類抽出物の原料となる豆類の形状としては、特に制限はされないが、油脂を含有した豆類、脱皮豆類、又はフレーク豆類等が好ましい。更に、豆類抽出物は、いかなる方法で製造されたものであってもよいが、例えば、原料となる豆類を水につけた後、水又は0.5〜1.0質量%の炭酸ナトリウムを含む水を添加してミキサー等により粉砕し、ろ過処理等によりおからを除去したものを利用することが好ましく、適宜、加熱処理を施してもよい。なお、上記水の温度は限定されず、熱水等も包含される。また、この豆類抽出物を含有する培地は、豆類抽出物由来の固形分濃度が5〜20質量%(以下、単に「%」で示す)のものを用いることが好ましい。 The shape of the beans used as the raw material of the bean extract is not particularly limited, but preferred are beans containing fats and oils, molted beans, or flake beans. Further, the bean extract may be produced by any method. For example, after the bean used as a raw material is soaked in water, water or water containing 0.5 to 1.0% by mass of sodium carbonate is used. It is preferable to use a material that has been added, pulverized with a mixer, etc., and okara removed by filtration or the like, and may be appropriately subjected to heat treatment. In addition, the temperature of the said water is not limited, A hot water etc. are included. Moreover, it is preferable to use the culture medium containing this bean extract having a solid content concentration derived from the bean extract of 5 to 20% by mass (hereinafter simply indicated as “%”).
前記発酵原料である培地には、必要に応じ、発酵処理に先立ち、ショ糖、ブドウ糖、果糖、転化糖等の食品に用いられる糖類等、肉エキス、酵母エキス、ビタミン類、ペプチド、アミノ酸類、ミネラル類、塩類、界面活性剤、脂肪酸、金属類等の微生物の増殖に必要な栄養素等を添加してもよい。また、原料を微生物の至適pHに調整するために、クエン酸、リンゴ酸、アスコルビン酸、乳酸、酢酸等の食品に用いられる酸を添加してもよい。 In the medium that is the fermentation raw material, if necessary, prior to fermentation treatment, sugars used in foods such as sucrose, glucose, fructose, invert sugar, meat extract, yeast extract, vitamins, peptides, amino acids, Nutrients necessary for the growth of microorganisms such as minerals, salts, surfactants, fatty acids and metals may be added. Moreover, in order to adjust a raw material to the optimal pH of microorganisms, you may add the acid used for foodstuffs, such as a citric acid, malic acid, ascorbic acid, lactic acid, and an acetic acid.
上記の発酵生成物を製造するために使用される微生物は、ビフィドバクテリウム属細菌または乳酸菌であれば特に限定されない。このうち、ビフィドバクテリウム属細菌の具体例としては、ビフィドバクテリウム・ブレーベ、ビフィドバクテリウム・ロンガム、ビフィドバクテリウム・インファンティス、ビフィドバクテリウム・アドレスセンティス、ビフィドバクテリウム・ビフィダム、ビフィドバクテリウム・アンギュラータム、ビフィドバクテリウム・カテニュラータム等が挙げられ、乳酸菌に属する微生物の具体例としては、ラクトバチルス属、ストレプトコッカス属、ラクトコッカス属、ペディオコッカス属、ロイコノストック属等に属する微生物が挙げられる。これらの微生物は、1種または2種以上を用いてもよい。 The microorganism used for producing the fermentation product is not particularly limited as long as it is a Bifidobacterium bacterium or a lactic acid bacterium. Among these, specific examples of Bifidobacterium include Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Bifidobacterium addresscentis, Bifidobacterium・ Bifidum, Bifidobacterium angularum, Bifidobacterium catenatum, etc. are mentioned, and specific examples of microorganisms belonging to lactic acid bacteria include Lactobacillus, Streptococcus, Lactococcus, Pediococcus, Leuco Examples include microorganisms belonging to the genus Nostock. These microorganisms may be used alone or in combination of two or more.
この中でも、原料に豆類抽出物を含有する培地を使用する場合には、ビフィドバクテリウム属細菌が好ましく、ビフィドバクテリウム・ブレーベがより好ましく、ビフィドバクテリウム・ブレーベ YIT 4065(FERM BP−6223、寄託日:平成8年(1996年)2月29日)、ビフィドバクテリウム・ブレーベ YIT 12272(FERM BP−11320、寄託日:2010年2月16日)が特に好ましい。なお、上記ビフィドバクテリウム・ブレーベ株のうち、ビフィドバクテリウム・ブレーベ YIT 4065は、通商産業省工業技術院生命工学工業技術研究所(日本国 茨城県つくば市東1丁目1番3号(郵便番号305)に寄託されていたが、現在は、独立行政法人製品評価技術基盤機構特許生物寄託センター(日本国 千葉県木更津市かずさ鎌足2丁目5番地8 120号室(郵便番号292−0818))に移転している。また、上記ビフィドバクテリウム・ブレーベ株のうち、ビフィドバクテリウム・ブレーベYIT 12272は、独立行政法人産業技術総合研究所 特許生物寄託センター(日本国 茨城県つくば市東1丁目1番地1 中央第6(郵便番号305−8566))に寄託されていたが、現在は、上記独立行政法人製品評価技術基盤機構 特許生物寄託センターに移転している。 Among these, when using a medium containing a bean extract as a raw material, Bifidobacterium bacteria are preferable, Bifidobacterium breve is more preferable, Bifidobacterium breve YIT 4065 (FERM BP- 6223, deposit date: February 29, 1996), Bifidobacterium breve YIT 12272 (FERM BP-11320, deposit date: February 16, 2010) is particularly preferred. Of the above Bifidobacterium breve strains, Bifidobacterium breve YIT 4065 is the Institute of Biotechnology, Institute of Industrial Science and Technology, Ministry of International Trade and Industry (1-3 Higashi 1-chome, Tsukuba, Ibaraki, Japan) No. 305), but now, the National Center for Biological Biology, National Institute for Product Evaluation and Technology (Room No. 120, 2-5, Kazusa Kamashi, Kisarazu-shi, Chiba, Japan (zip code 292-0818)) Among the above Bifidobacterium breve strains, Bifidobacterium breve YIT 12272 is an independent administrative agency, National Institute of Advanced Industrial Science and Technology, Patent Biological Deposit Center (1st East, Tsukuba City, Ibaraki Prefecture, Japan) No. 1 No. 1 Central No. 6 (zip code 305-8666)), but now the above-mentioned independent administrative corporation product evaluation Operative foundation mechanism has been transferred to the International Patent Organism Depositary.
上記発酵生成物の製造において培養は、上記菌株を複数種組合せた混合発酵であってもよいし、菌株を複数種組合せた連続発酵であってもよい。その培養に当たっては、前記以外の微生物として、バチルス属、アセトバクター属、グルコノバクター属等の細菌類、あるいはサッカロミセス属、キャンディダ属、ロドトルーラ属、ピチア属、シゾサッカロミセス属、トルラ属、チゴサッカロミセス属等の酵母類、あるいはアスペルギルス属、ユウロチウム属、モナスカス属、ムコール属、ニューロスポラ属、ペニシリウム属、リゾープス属等の糸状菌類を更に使用することもできる。 In the production of the fermentation product, the culturing may be mixed fermentation in which a plurality of strains are combined, or continuous fermentation in which a plurality of strains are combined. In the culture, microorganisms other than the above include bacteria such as Bacillus genus, Acetobacter genus, Gluconobacter genus, or Saccharomyces genus, Candida genus, Rhodotorula genus, Pichia genus, Schizosaccharomyces genus, Torula genus, Tigo genus Yeasts such as Saccharomyces, or filamentous fungi such as Aspergillus, Eurothium, Monascus, Mucor, Neurospora, Penicillium, Rhizopus and the like can also be used.
前記のように調製した原料培地に上記微生物を作用させる方法は特に限定されず、例えば、予め培養した微生物の菌液を上記培地中に0.01〜10%、好ましくは0.1〜5%接種した後、20〜45℃、好ましくは25〜42℃で5〜96時間、好ましくは10〜60時間培養すればよい。また、この時の他の培養条件としては、静置、攪拌、振盪、通気、嫌気等が挙げられ、微生物に応じ、これらから培養に適した方法を適宜選択して行えばよい。 The method of allowing the microorganism to act on the raw material medium prepared as described above is not particularly limited. For example, 0.01 to 10%, preferably 0.1 to 5%, of a microorganism solution cultured in advance in the medium. After inoculation, the cells may be cultured at 20 to 45 ° C., preferably 25 to 42 ° C. for 5 to 96 hours, preferably 10 to 60 hours. In addition, other culture conditions at this time include standing, stirring, shaking, aeration, anaerobic and the like, and a method suitable for culture may be appropriately selected from these according to the microorganism.
斯くして得られた発酵生成物はそのまま使用することもできるが、更に、公知のろ過、透析、遠心分離等の分離や精製処理、溶媒等による抽出処理、加熱処理、脱臭処理、pH調整、凍結乾燥処理、濃縮乾固処理等を施すことができる。また、遠心分離、ろ過等により高分子物質や不溶性物質を除去して使用することが好ましく、特に、エタノール等の低級アルコールや、1,3−ブチレングリコール等の多価アルコールを添加した後、遠心分離、ろ過等の処理を行うことが好ましい。 The fermentation product thus obtained can be used as it is, but further, known filtration, dialysis, separation such as centrifugation, purification treatment, extraction treatment with a solvent, heat treatment, deodorization treatment, pH adjustment, Freeze-drying treatment, concentration-drying treatment, etc. can be performed. In addition, it is preferable to use after removing a polymer substance or an insoluble substance by centrifugation, filtration or the like, and in particular, after adding a lower alcohol such as ethanol or a polyhydric alcohol such as 1,3-butylene glycol, centrifugation is performed. It is preferable to perform treatments such as separation and filtration.
以上のようにして得られた発酵生成物は、公知の医薬品、皮膚外用剤あるいは化粧料で利用される成分と適宜配合し、所望の形態のコラーゲン増強剤とすることができる。 The fermentation product obtained as described above can be appropriately blended with components used in known pharmaceuticals, topical skin preparations, or cosmetics to obtain a desired form of collagen enhancer.
このコラーゲン増強剤の形態としては、正常なコラーゲン組織に修復することが求められる部位(患部)に注射等で直接注入投与したり、その部位に近接する皮膚上に塗布、貼付するなどして投与する形の、医薬品、皮膚外用剤あるいは化粧料の形態を挙げることができる。具体的な製品の形態の例としては、注射剤、液剤、軟膏剤、乳液剤、クリーム剤、貼付剤、テープ剤、パック剤、入浴剤等が挙げられ、特に乳液剤、クリーム剤または液剤が好ましい。また、別の形態としては、再生医療のために人工的に作られる組織、例えば人工皮膚の培養時に添加する添加剤を挙げることができる。 As a form of this collagen enhancer, it is administered by direct injection by injection or the like to a site (affected area) required to restore normal collagen tissue, or by applying or pasting on the skin adjacent to the site. The form of the medicine, the external preparation for skin, or the cosmetic can be mentioned. Specific examples of product forms include injections, liquids, ointments, emulsions, creams, patches, tapes, packs, bathing agents, and the like, and in particular, emulsions, creams or liquids. preferable. Further, as another form, an additive added at the time of culturing a tissue artificially made for regenerative medicine, for example, artificial skin, can be mentioned.
このコラーゲン増強剤には、上記投与形態に応じた量の発酵生成物が配合される。この量は、特に限定されるものではないが、例えば組成物中、発酵生成物として0.0001〜50%、好ましくは0.01〜20%、特に好ましくは0.5〜10%配合すればよい。 The collagen enhancer is blended with an amount of fermentation product according to the dosage form. This amount is not particularly limited. For example, in the composition, 0.0001 to 50%, preferably 0.01 to 20%, particularly preferably 0.5 to 10% as a fermentation product. Good.
また、本発明のコラーゲン増強剤の製造に当たっては、その効果を阻害しない範囲で、医薬品類、医薬部外品類、化粧品類、浴用剤などにおいて通常用いられている原料、例えば、界面活性剤、油分、アルコール類、保湿剤、増粘剤、水溶性高分子、防腐剤、酸化防止剤、キレート剤、pH調整剤、発泡剤、香料、色素、顔料、紫外線吸収・散乱剤、粉体、ビタミン類、アミノ酸類、抗菌剤、植物抽出物、動物由来成分、海藻抽出物、各種薬剤、添加剤、水等を任意成分として配合することができる。 In the production of the collagen enhancer of the present invention, raw materials usually used in pharmaceuticals, quasi drugs, cosmetics, bathing agents, etc., for example, surfactants, , Alcohols, moisturizers, thickeners, water-soluble polymers, preservatives, antioxidants, chelating agents, pH adjusters, foaming agents, fragrances, dyes, pigments, UV absorbers / scatterers, powders, vitamins Amino acids, antibacterial agents, plant extracts, animal-derived components, seaweed extracts, various drugs, additives, water, and the like can be blended as optional components.
このうち、界面活性剤としては、モノラウリン酸ソルビタン、モノパルミチン酸ソルビタン、セスキオレイン酸ソルビタン、トリオレイン酸ソルビタン、モノラウリン酸ポリオキシエチレンソルビタン、モノステアリン酸ポリオキセチレンソルビタン、ポリエチレングリコールモノオレート、ポリエチレングリコールアルキレート、ポリオキシエチレンアルキルエーテル、ポリグリコールジエーテル、ラウロイルジエタノールアマイド、脂肪酸イソプロパノールアマイド、マルチトールヒドロキシ脂肪酸エーテル、アルキル化多糖、アルキルグルコシド、シュガーエステル等の非イオン性界面活性剤、親油型グリセリンモノステアレート、自己乳化型グリセリンモノステアレート、ポリグリセリンモノステアレート、ポリグリセリンアルキレート、ソルビタンモノオレート、ポリエチレングリコールモノステアレート、ポリオキシエチレンソルビタンモノオレート、ポリオキシエチレンセチルエーテル、ポリオキシエチレン化ステロール、ポリオキシエチレン化ラノリン、ポリオキシエチレン化蜜ロウ、ポリオキシエチレン硬化ヒマシ油等のノニオン性界面活性剤、ステアリン酸ナトリウム、パルミチン酸カリウム、セチル硫酸ナトリウム、ラウリルリン酸ナトリウム、ポリオキシエチレンラウリル硫酸ナトリウム、パルミチン酸トリエタノールアミン、ポリオキシエチレンラウリルリン酸ナトリウム、N−アシルグルタミン酸ナトリウム等のアニオン性界面活性剤、塩化ステアリルジメチルベンジルアンモニウム、塩化ステアリルトリメチルアンモニウム、塩化ベンザルコニウム、ラウリルアミンオキサイド等のカチオン性界面活性剤、塩酸アルキルアミノエチルグリシン液、レシチン等の両性界面活性剤等を例示することができる。 Among these, sorbitan monolaurate, sorbitan monopalmitate, sorbitan sesquioleate, sorbitan trioleate, polyoxyethylene sorbitan monolaurate, polyoxetylene sorbitan monostearate, polyethylene glycol monooleate, polyethylene glycol Non-ionic surfactant such as alkylate, polyoxyethylene alkyl ether, polyglycol diether, lauroyl diethanolamide, fatty acid isopropanol amide, maltitol hydroxy fatty acid ether, alkylated polysaccharide, alkyl glucoside, sugar ester, lipophilic glycerin Monostearate, self-emulsifying glycerin monostearate, polyglycerin monostearate, polyglycerin alkyle Sorbitan monooleate, polyethylene glycol monostearate, polyoxyethylene sorbitan monooleate, polyoxyethylene cetyl ether, polyoxyethylenated sterol, polyoxyethylenated lanolin, polyoxyethylenated beeswax, polyoxyethylene hydrogenated castor oil Nonionic surfactant such as sodium stearate, potassium palmitate, sodium cetyl sulfate, sodium lauryl phosphate, sodium polyoxyethylene lauryl sulfate, triethanolamine palmitate, sodium polyoxyethylene lauryl phosphate, N-acyl glutamic acid Anionic surfactants such as sodium, stearyldimethylbenzylammonium chloride, stearyltrimethylammonium chloride, benzalkonium chloride Cationic surfactants such as lauryl amine oxide, hydrochloric alkylamino ethyl glycine solution, can be exemplified amphoteric surfactants such as lecithin.
油分としては、マカデミアナッツ油、ヒマシ油、オリーブ油、カカオ油、椿油、ヤシ油、木ロウ、ホホバ油、グレープシード油、アボガド油等の植物油脂類、ミンク油、卵黄油等の動物油脂類、蜜ロウ、鯨ロウ、ラノリン、カルナウバロウ、キャンデリラロウ等のロウ類、流動パラフィン、スクワラン、マイクロクリスタリンワックス、セレシンワックス、パラフィンワックス、ワセリン等の炭化水素類、ラウリン酸、ミリスチン酸、ステアリン酸、オレイン酸、イソステアリン酸、ベヘニン酸、パルミチン酸、カプリン酸、ラノリン脂肪酸、リノール酸、リノレン酸等の天然および合成脂肪酸類、セタノール、ステアリルアルコール、ヘキシルデカノール、オクチルドデカノール、ラウリルアルコール、カプリルアルコール、ミリスチルアルコール、セチルアルコール、コレステロール、フィトステロール等の天然および合成高級アルコール類、ミリスチン酸イソプロピル、パルミチン酸イソプロピル、ミリスチン酸オクチルドデシル、オレイン酸オクチルドデシル、コレステロールオレエート等のエステル類等を例示することができる。 Oils include vegetable oils such as macadamia nut oil, castor oil, olive oil, cacao oil, coconut oil, palm oil, tree wax, jojoba oil, grape seed oil, avocado oil, animal oils such as mink oil and egg yolk oil, honey Waxes such as wax, whale wax, lanolin, carnauba wax and candelilla wax, hydrocarbons such as liquid paraffin, squalane, microcrystalline wax, ceresin wax, paraffin wax, petrolatum, lauric acid, myristic acid, stearic acid, oleic acid , Natural and synthetic fatty acids such as isostearic acid, behenic acid, palmitic acid, capric acid, lanolin fatty acid, linoleic acid, linolenic acid, cetanol, stearyl alcohol, hexyldecanol, octyldodecanol, lauryl alcohol, capryl alcohol, myristylua Call, natural and synthetic higher alcohols such as cetyl alcohol, cholesterol, phytosterol, may isopropyl myristate, isopropyl palmitate, octyldodecyl myristate, octyldodecyl oleate, be exemplified by esters such as cholesterol oleate.
保湿剤としては、グリセリン、エリスリトール、キシリトール、マルチトール、プロピレングリコール、1,3−ブチレングリコール、ソルビトール、ポリグリセリン、ポリエチレングリコール、ジプロピレングリコール、1,2−ペンタンジオール等のペンチレングリコール類、イソプレングリコール等の多価アルコール類、アミノ酸、乳酸ナトリウム、ピロリドンカルボン酸ナトリウム等の天然保湿成分(NMF)、キシログルカン、クインスシード、カラギーナン、ペクチン、マンナン、カードラン、ガラクタン、デルマタン硫酸、グリコーゲン、ケラタン硫酸、コンドロイチン、ムコイチン硫酸、ケラト硫酸、ローカストビーンガム、サクシノグルカン、カロニン酸、ヘパラン硫酸、ヒアルロン酸ナトリウム、ヒアルロン酸、コラーゲン、ムコ多糖類、コンドロイチン硫酸等の水溶性高分子物質等を例示することができる。 Examples of humectants include glycerin, erythritol, xylitol, maltitol, propylene glycol, 1,3-butylene glycol, sorbitol, polyglycerin, polyethylene glycol, dipropylene glycol, 1,2-pentanediol, and other pentylene glycols, isoprene. Polyhydric alcohols such as glycol, natural moisturizing ingredients (NMF) such as amino acids, sodium lactate, sodium pyrrolidone carboxylate, xyloglucan, quince seed, carrageenan, pectin, mannan, curdlan, galactan, dermatan sulfate, glycogen, keratan sulfate , Chondroitin, mucoitin sulfate, keratosulfate, locust bean gum, succinoglucan, caronic acid, heparan sulfate, sodium hyaluronate, hyaluronic acid, coller Emissions can be exemplified mucopolysaccharide, water-soluble polymer such as chondroitin sulfate.
増粘剤としては、アルギン酸ナトリウム、キサンタンガム、硅酸アルミニウム、マルメロ種子抽出物、トラガントガム、デンプン、アラビアガム、ヒドロキシエチルグァーガム、カルボキシメチルグァーガム、グァーガム、デキストラン、キチン、キトサン、カルボキシメチルキチン、寒天等の天然高分子物質、メチルセルロース、ヒドロキシエチルセルロース、カルボキシメチルセルロース、可溶性デンプン、カチオン化セルロース等の半合成高分子物質、カルボキシビニルポリマー、ポリビニルアルコール、アクリル酸メタクリル酸アルキル共重合体等の合成高分子物質等を例示することができる。 Thickeners include sodium alginate, xanthan gum, aluminum oxalate, quince seed extract, tragacanth gum, starch, gum arabic, hydroxyethyl guar gum, carboxymethyl guar gum, guar gum, dextran, chitin, chitosan, carboxymethyl chitin, agar, etc. Natural polymer materials, semi-synthetic polymer materials such as methylcellulose, hydroxyethylcellulose, carboxymethylcellulose, soluble starch, and cationized cellulose, synthetic polymer materials such as carboxyvinyl polymer, polyvinyl alcohol, and alkyl methacrylate methacrylate copolymer It can be illustrated.
防腐剤としては、安息香酸塩、サリチル酸塩、ソルビン酸塩、デヒドロ酢酸塩、パラオキシ安息香酸エステル、2,4,4’−トリクロロ−2’−ヒドロキシジフェニルエーテル、3,4,4’−トリクロロカルバニリド、塩化ベンザルコニウム、ヒノキチオール、レゾルシン、エタノール等を例示することができる。 Examples of preservatives include benzoate, salicylate, sorbate, dehydroacetate, p-hydroxybenzoate, 2,4,4′-trichloro-2′-hydroxydiphenyl ether, 3,4,4′-trichlorocarbani Lido, benzalkonium chloride, hinokitiol, resorcin, ethanol and the like can be exemplified.
酸化防止剤としては、ジブチルヒドロキシトルエン、ブチルヒドロキシアニソール、没食子酸プロピル、アスコルビン酸等を、キレート剤としては、エデト酸塩、ピロリン酸塩、ヘキサメタリン酸塩、クエン酸、酒石酸、グルコン酸等を、pH調整剤としては、水酸化ナトリウム、トリエタノールアミン、クエン酸、クエン酸ナトリウム、ホウ酸、ホウ砂、リン酸水素カリウム等をそれぞれ例示することができる。 As an antioxidant, dibutylhydroxytoluene, butylhydroxyanisole, propyl gallate, ascorbic acid, etc., and as a chelating agent, edetate, pyrophosphate, hexametaphosphate, citric acid, tartaric acid, gluconic acid, etc. Examples of the pH adjuster include sodium hydroxide, triethanolamine, citric acid, sodium citrate, boric acid, borax, and potassium hydrogen phosphate.
紫外線吸収・散乱剤としては、パラアミノ安息香酸系紫外線吸収剤、アントラニル酸系紫外線吸収剤、サリチル酸系紫外線吸収剤、桂皮酸系紫外線吸収剤、ベンゾフェノン系紫外線吸収剤、糖系紫外線吸収剤、3−(4’−メチルベンジリデン)−d−カンファー、3−ベンジリデン−d,1−カンファー、ウロカニン酸、ウロカニン酸エチルエステル、2−フェニル−5−メチルベンゾキサゾール、2−(2’−ヒドロキシ−5’−t−オクチルフェニル)ベンゾトリアゾール、2−(2’−ヒドロキシ−5’−メチルフェニル)ベンゾトリアゾール、ジベンザラジン、ジアニソイルメタン、4−メトキシ−4’−t−ブチルジベンゾイルメタン、5−(3,3−ジメチル−2−ノルボルニリデン)−3−ペンタン−2−オン、2−ヒドロキシ−4−メトキシベンゾフェノン、オクチルジメチルパラアミノベンゾエート、エチルヘキシルパラメトキシシンナメート、酸化チタン、カオリン、タルク等を例示することができる。 Examples of UV absorbers / scatterers include p-aminobenzoic acid UV absorbers, anthranilic acid UV absorbers, salicylic acid UV absorbers, cinnamic acid UV absorbers, benzophenone UV absorbers, sugar UV absorbers, 3- (4′-methylbenzylidene) -d-camphor, 3-benzylidene-d, 1-camphor, urocanic acid, urocanic acid ethyl ester, 2-phenyl-5-methylbenzoxazole, 2- (2′-hydroxy-5) '-T-octylphenyl) benzotriazole, 2- (2'-hydroxy-5'-methylphenyl) benzotriazole, dibenzalazine, dianisoylmethane, 4-methoxy-4'-t-butyldibenzoylmethane, 5- ( 3,3-dimethyl-2-norbornylidene) -3-pentan-2-one, 2-hydro Shi-4-methoxybenzophenone, octyl dimethyl para amino benzoate, can be exemplified ethylhexyl p-methoxycinnamate, titanium oxide, kaolin, talc and the like.
ビタミン類としては、ビタミンB6塩酸塩、ビタミンB6トリパルミテート、ビタミンB6ジオクタノエ−ト、ビタミンB2およびその誘導体、ビタミンB12、ビタミンB15およびその誘導体等のビタミンB類、アスコルビン酸、アスコルビン酸硫酸エステルおよびその塩、アスコルビン酸リン酸エステルおよびその塩、アスコルビン酸ジパルミテート、アスコルビン酸グルコシド、アシルアスコルビン酸グルコシド、アスコルビン酸テトライソパルミテート等のビタミンC類、ビタミンD、α−トコフェロール、β−トコフェロール、γ−トコフェロール、ビタミンEアセテート等のビタミンE類、ビタミンF、ビタミンK、パントテン酸、パンテチン、ビタミンH、ビタミンP、ビタミンU、カルニチン、フェルラ酸、γ−オリザノール、α−リポ酸、オロット酸およびそれらの誘導体等を例示することができる。As vitamins, vitamin B 6 hydrochloride, vitamin B 6 tripalmitate, vitamin B 6 dioctanoate, vitamin B 2 and its derivatives, vitamin B 12 such as vitamin B 12 , vitamin B 15 and its derivatives, ascorbic acid Ascorbic acid sulfate and its salts, Ascorbic acid phosphate and its salts, Ascorbic acid dipalmitate, Ascorbic acid glucoside, Acyl ascorbic acid glucoside, Ascorbic acid tetraisopalmitate, etc. Vitamin C, Vitamin D, α-tocopherol, Vitamin E such as β-tocopherol, γ-tocopherol, vitamin E acetate, vitamin F, vitamin K, pantothenic acid, pantethine, vitamin H, vitamin P, vitamin U, carnitine, ferulic acid, γ-oryza Lumpur, alpha-lipoic acid, can be exemplified orotic acid and their derivatives.
アミノ酸類としては、グリシン、アラニン、バリン、ロイシン、イソロイシン、セリン、トレオニン、フェニルアラニン、チロシン、アスパラギン、グルタミン、タウリン、トリプトファン、シスチン、システイン、メチオニン、プロリン、ヒドロキシプロリン、アスパラギン酸、グルタミン酸、アルギニン、ヒスチジン、リジンおよびそれらの誘導体等を例示することができる。 Amino acids include glycine, alanine, valine, leucine, isoleucine, serine, threonine, phenylalanine, tyrosine, asparagine, glutamine, taurine, tryptophan, cystine, cysteine, methionine, proline, hydroxyproline, aspartic acid, glutamic acid, arginine, histidine. And lysine and derivatives thereof.
抗菌剤としては、安息香酸、サリチル酸、ソルビン酸、パラオキシ安息香酸エステル、ヘキサクロロフェン等を例示することができる。 Examples of the antibacterial agent include benzoic acid, salicylic acid, sorbic acid, p-hydroxybenzoic acid ester, hexachlorophene and the like.
植物抽出物としては、フユボダイジュ、ギシギシ、クララ、コウホネ、オレンジ、セージ、ノコギリソウ、ゼニアオイ、センブリ、タイム、トウキ、トウヒ、バーチ、スギナ、ヘチマ、マロニエ、ユキノシタ、アルニカ、ユリ、ヨモギ、シャクヤク、アロエ、クチナシ、サワラ、ブクリョウ、サンシシ、オウゴン、甘草、カワラヨモギ、クジン、ヨクイニン、ニンドウ、シャクヤク、ソウハクヒ、サンザシ、ボタンピ、セファランチン等からの抽出物を例示することができる。 Plant extracts include scallops, borage, clara, corn, orange, sage, yarrow, mallow, thyme, thyme, spruce, spruce, birch, horsetail, loofah, maronier, yukinoshita, arnica, lily, mugwort, peonies, aloe Examples include extracts from gardenia, sawara, bukuryo, sanshishi, ougon, licorice, kawara mugwort, kujin, yokuinin, nindou, peonies, sakuhakuhi, hawthorn, buttonpi, cephalanthin and the like.
海藻抽出物としては、アスコフィルム、コンブ、マコンブ、ワカメ、ヒジキ、ヒバマタ、モズク、オキナワモズク、ヒマンタリア等の褐藻類、テングサ、サンゴモ、パルマリア、ツノマタ、ノリ等の紅藻類、アオサ、アナアオサ等の緑藻類、藍藻類からの抽出物を例示することができる。 As seaweed extracts, brown algae such as Ascofilm, kombu, macomb, wakame, hijiki, hibamata, mozuku, okinawa mozuku, himantalia, red algae such as primrose, coral, palmaria, tsunomata, nori, green algae such as aosa, anaaaosa An example is an extract from cyanobacteria.
各種薬剤としては、ニコチン酸アミド、ニコチン酸ベンジル、γ−オリザノール、アラントイン、グリチルリチン酸およびその塩、グリチルレチン酸およびその誘導体、ヒノキチオール、ビサボロール、ユーカルプトーン、チモール、イノシトール、サイコサポニン、ニンジンサポニン、ヘチマサポニン、ムクロジサポニン等のサポニン類、パントテニルエチルエーテル、エチニルエストラジオール、トラネキサム酸、アルブチン、プラセンタエキス等を例示することができる。 Various drugs include nicotinamide, benzyl nicotinate, γ-oryzanol, allantoin, glycyrrhizic acid and its salts, glycyrrhetinic acid and its derivatives, hinokitiol, bisabolol, eucarptone, thymol, inositol, saikosaponin, carrot saponin, and loofah Examples thereof include saponins such as saponin and muclodisaponin, pantothenyl ethyl ether, ethinyl estradiol, tranexamic acid, arbutin, and placenta extract.
これらの原料の中でも、特に、コラーゲン産生促進作用、またはコラーゲンの分解を阻害する作用を有する原料を併用することが好ましく、これらの効果を有する原料としては、フユボダイジュエキス、アスコフィルムノドスムエキス、アスコルビン酸、アスコルビン酸硫酸エステルおよびその塩、アスコルビン酸リン酸エステルおよびその塩、アスコルビン酸ジパルミテート、アスコルビン酸グルコシド、アシルアスコルビン酸グルコシド、アスコルビン酸テトライソパルミテート等のビタミンC類があげられる。 Among these raw materials, in particular, it is preferable to use a raw material having a collagen production promoting action or a collagen inhibiting action in combination, and examples of the raw material having these effects include Fuyubodaiju extract, Ascofilm nodosum extract, Ascorbic acid, ascorbic acid sulfate and its salt, ascorbic acid phosphate and its salt, ascorbic acid dipalmitate, ascorbic acid glucoside, acylascorbic acid glucoside, ascorbic acid tetraisopalmitate and the like can be mentioned.
以上のようにして得られるコラーゲン増強剤は、事故、疾病等により強度が低下したコラーゲンを含む生体組織、すなわち、靭帯、腱、軟骨、皮膚、歯周組織等の生体組織に使用しその組織の修復を行う、あるいはその組織の強度低下を予防することができる。 The collagen enhancer obtained as described above is used for biological tissues containing collagen whose strength has been reduced due to accidents, diseases, etc., that is, biological tissues such as ligaments, tendons, cartilage, skin, periodontal tissues, etc. Restoration can be performed, or strength reduction of the tissue can be prevented.
例えば、膝の軟骨は、コラーゲン線維によって弾力性が維持されているが、コラーゲンの強度が減少すると、クッションの働きが低下して、軟骨がつぶれやすくなるため痛みが発生し、さらにひどくなると変形性関節症の原因となる。これに対し、本発明のコラーゲン増強剤を、例えば膝関節などの損傷した部位に、直接注射等により投与することで、周辺組織中のプロテオグリカン産生が促進され、コラーゲン結束能が増強し、軟骨の強度を増すことができるため、軟骨がすり減ることを防ぐことが可能である。 For example, the elasticity of knee cartilage is maintained by collagen fibers, but when the strength of collagen decreases, the function of the cushion decreases and the cartilage tends to collapse, causing pain and deforming when it gets worse. Causes arthropathy. In contrast, by administering the collagen enhancer of the present invention directly to an injured site such as the knee joint by direct injection or the like, proteoglycan production in the surrounding tissue is promoted, collagen binding ability is enhanced, Since the strength can be increased, it is possible to prevent the cartilage from being worn away.
また、歯周病にかかると歯周組織の構成成分であるコラーゲン組織も破壊されてしまうため、歯周組織の治療時に、コラーゲンを再生し歯茎を正常化させるためには、コラーゲン線維を束ね、強化することが重要である。これに対し、本発明のコラーゲン増強剤を歯磨き剤等に混ぜて使用することで、歯肉中のプロテオグリカン産生を促進し、コラーゲン結束能を増強することができるので、歯茎の後退を修復・予防するとともに、上記のような歯周病により損傷を受けた歯茎に対してもその治療・改善のサポートになるので、歯茎の維持や歯周病からの正常化に有効なものである。 In addition, collagen tissue that is a component of periodontal tissue is also destroyed when suffering from periodontal disease, so in order to regenerate collagen and normalize gums during periodontal tissue treatment, bundle collagen fibers, It is important to strengthen. On the other hand, by using the collagen enhancer of the present invention mixed with a dentifrice or the like, proteoglycan production in the gums can be promoted and collagen binding ability can be enhanced, thereby repairing / preventing gum recession. At the same time, the treatment and improvement of the gums damaged by the above-mentioned periodontal diseases can be supported, so that it is effective in maintaining gums and normalizing from periodontal diseases.
更に腱や靱帯は、骨と筋肉や、骨同士を結合するという役割を果たすもので、運動の際に大きな力がかかる組織であり、無理な力が加わると損傷しやすいことが知られている。このように損傷した腱や靱帯に本発明のコラーゲン増強剤を使用することで、それらの回復のサポートになる。 Furthermore, tendons and ligaments play a role in connecting bones and muscles, and bones, and are a tissue that exerts a large force during exercise, and are known to be easily damaged when excessive force is applied. . By using the collagen enhancer of the present invention for the tendons and ligaments damaged in this way, it helps to recover them.
また更に、事故や手術等で損傷した、傷痕となるような皮膚組織の修復にも本発明のコラーゲン増強剤は有用なものである。本発明のコラーゲン増強剤を、損傷した皮膚組織に直接塗布、注射等により投与することで、皮膚組織中のプロテオグリカン産生が促進され、コラーゲン結束能が増強し、皮膚組織の修復を促進することができる。 Furthermore, the collagen enhancer of the present invention is also useful for repairing skin tissue that has been damaged by an accident or surgery, resulting in scars. By applying the collagen enhancer of the present invention directly to damaged skin tissue by injection, injection, etc., proteoglycan production in the skin tissue is promoted, collagen binding ability is enhanced, and skin tissue repair is promoted. it can.
なお、本発明のコラーゲン増強剤は、生体に直接でなく、コラーゲン組織を利用する人工皮膚や再生医療のために人工的に作られる血管等において、その培養中や、適用時等において添加使用することで再生組織の強度を強めることができる。例えば、人工皮膚、人工血管等の再生組織を培養する際に、本発明のコラーゲン増強剤を培地に添加する、あるいは再生組織を組織欠損部分へ適用する際に、本発明のコラーゲン増強剤を再生組織に塗布、注射等により添加することで、再生組織中のプロテオグリカン産生を促進し、コラーゲン結束能を増強することができるので、再生組織の強度を増強させることが可能となる。 In addition, the collagen enhancer of the present invention is used not only directly in the living body but also in artificial skin using collagen tissue or blood vessels artificially created for regenerative medicine, during its cultivation, application, etc. Thus, the strength of the regenerated tissue can be increased. For example, when a regenerated tissue such as artificial skin or artificial blood vessel is cultured, the collagen enhancer of the present invention is added to the medium, or when the regenerated tissue is applied to a tissue defect part, the collagen enhancer of the present invention is regenerated. By adding to the tissue by application, injection or the like, proteoglycan production in the regenerated tissue can be promoted and collagen binding ability can be enhanced, so that the strength of the regenerated tissue can be enhanced.
次に製造例、試験例および製剤例を挙げ、本発明を更に詳しく説明するが、本発明はこれらに何ら制約されるものではない。 Next, although a manufacture example, a test example, and a formulation example are given and this invention is demonstrated in more detail, this invention is not restrict | limited at all by these.
製 造 例 1
発酵生成物の製造(1):
大豆フレークを水洗後、水に一夜浸漬して十分に吸水させた。この大豆に4重量倍の水を加えてミキサーでペースト状に粉砕した。これを100℃で30分間加熱し、冷却後濾過したものを100℃で90分間蒸気滅菌して豆乳を製造した(固形分濃度約10質量%)。Manufacturing example 1
Production of fermentation product (1):
Soy flakes were washed with water and immersed in water overnight to allow sufficient water absorption. Four times by weight of water was added to the soybean and pulverized into a paste using a mixer. This was heated at 100 ° C. for 30 minutes, cooled and filtered, and steam sterilized at 100 ° C. for 90 minutes to produce soy milk (solid content concentration of about 10% by mass).
前培養したビフィドバクテリウム・ブレーベ YIT 4065(FERM BP−6223)の菌液を豆乳の全量の1.0%になるように接種した後、窒素雰囲気中、30℃で45時間培養した。得られた発酵豆乳の生菌数は、約1X107cells/mlであった。この発酵豆乳をろ紙にて濾過し、発酵生成物1を製造した。After inoculating a pre-cultured Bifidobacterium breve YIT 4065 (FERM BP-6223) solution to 1.0% of the total amount of soymilk, the cells were cultured in a nitrogen atmosphere at 30 ° C. for 45 hours. The number of viable bacteria of the obtained fermented soymilk was about 1 × 10 7 cells / ml. The fermented soymilk was filtered with a filter paper to produce a fermented product 1.
製 造 例 2
発酵生成物の製造(2):
製造例1と同様に製造した発酵豆乳に、3重量倍の1,3−ブチレングリコールを添加してろ紙にて濾過し、発酵生成物2を製造した。Manufacturing example 2
Production of fermentation product (2):
Fermented soymilk produced in the same manner as in Production Example 1 was added with 3 times the weight of 1,3-butylene glycol and filtered through filter paper to produce fermentation product 2.
製 造 例 3
発酵生成物の製造(3):
ビフィドバクテリウム・ブレーベ YIT 12272(FERM BP−11320)を使用する以外は、製造例1と同様にして発酵生成物3を製造した。Manufacturing example 3
Production of fermentation product (3):
Fermentation product 3 was produced in the same manner as in Production Example 1 except that Bifidobacterium breve YIT 12272 (FERM BP-11320) was used.
製 造 例 4
発酵生成物の製造(4):
ビフィドバクテリウム・ブレーベ YIT 12272(FERM BP−11320)を使用する以外は、製造例2と同様にして発酵生成物4を製造した。Manufacturing example 4
Production of fermentation product (4):
Fermentation product 4 was produced in the same manner as in Production Example 2 except that Bifidobacterium breve YIT 12272 (FERM BP-11320) was used.
試 験 例 1
デコリン量の測定(1)
(1)線維芽細胞(NHDF)を24ウエルプレートに播種し、D−MEM培地中で被覆率70〜80%になるまで培養した。次いで、培地中に発酵生成物1を1%または2%添加し、37℃で48時間培養した。なお、コントロールは発酵生成物を添加していないD−MEM培地を使用し同様に培養を行った。Test example 1
Measurement of decorin (1)
(1) Fibroblasts (NHDF) were seeded in a 24-well plate and cultured in D-MEM medium until the coverage was 70 to 80%. Subsequently, 1% or 2% of the fermentation product 1 was added to the medium, and cultured at 37 ° C. for 48 hours. In addition, as a control, D-MEM medium to which no fermentation product was added was used, and culture was performed in the same manner.
それぞれの培養上清中の産生されたデコリン量を以下のウェスタンブロット法により測定した。まず、培養上清について電気泳動を実施し、アクリルアミドゲル内の蛋白質を、セミドライ型転写装置を用いてイモビロンPVDFメンブランに転写した。転写後、メンブランをスキムミルクにてブロッキングし、一次抗体(マウス抗デコリン抗体)溶液に4℃で一晩浸した。さらにニ次抗体(HRP標識ヤギ抗マウスIgG抗体)溶液に室温で2時間浸した後、ChemilumiOneSuper(ナカライテスク)を用いてメンブラン上の目的蛋白質であるデコリンを検出した。検出されたバンドの発光強度を、MultiGauge(FUJI FILM)を用いて求めそれぞれの試料のデコリンの産生量を測定した。得られた値をコントロールのデコリン産生量で除し、コントロールに対するデコリンの相対量を算出した。この結果を表1に示す。 The amount of decorin produced in each culture supernatant was measured by the following Western blot method. First, electrophoresis was performed on the culture supernatant, and the protein in the acrylamide gel was transferred to the immobilon PVDF membrane using a semi-dry type transfer apparatus. After the transfer, the membrane was blocked with skim milk and immersed in a primary antibody (mouse anti-decolin antibody) solution at 4 ° C. overnight. Further, after immersing in a secondary antibody (HRP-labeled goat anti-mouse IgG antibody) solution at room temperature for 2 hours, decorin, which is the target protein on the membrane, was detected using ChemiluminescenceOneSuper (Nacalai Tesque). The emission intensity of the detected band was determined using MultiGauge (FUJI FILM), and the amount of decorin produced in each sample was measured. The obtained value was divided by the amount of decorin produced by the control, and the amount of decorin relative to the control was calculated. The results are shown in Table 1.
(2)(1)と同様の方法で24時間培養した細胞中から、RNeasy mini kit(QIAGEN)を用い、製品添付の説明書に沿ってRNAの抽出操作を行った。RNA抽出後、Revertra Ace qPCR RT kit(TOYOBO)を用いて逆転写反応を行いcDNAを合成した。RT−qPCRには、THUNDERBIRD SYBR qPCR kit(TOYOBO)を用い、7500 Realtime PCRシステム(Applied Biosystems)で以下の条件で増幅を行った。 (2) RNA was extracted from cells cultured for 24 hours in the same manner as in (1) using RNeasy mini kit (QIAGEN) according to the instructions attached to the product. After RNA extraction, reverse transcription was performed using Reverse Ace qPCR RT kit (TOYOBO) to synthesize cDNA. For RT-qPCR, a THUNDERBIRD SYBR qPCR kit (TOYOBO) was used, and amplification was performed with a 7500 Realtime PCR system (Applied Biosystems) under the following conditions.
(i)プライマー
ヒトデコリン センスプライマー 5’-ATGAAGGCCACTATCATCCTCC-3’
ヒトデコリン アンチセンスプライマー 5’-GTCGCGGTCATCAGGAACTT-3’
ヒト36B4 センスプライマー 5’-ATGCAGCAGATCCGCATGT-3’
ヒト36B4 アンチセンスプライマー 5’-TTGCGCATCATGGTGTTCTT-3’
(ii)反応条件
95℃ 、1分 1cycle
95℃、30秒→60℃、1分 40cycle
95℃、15秒→60℃、1分→95℃、15秒 1cycle(I) Primer Human decorin Sense primer 5'-ATGAAGGCCACTATCATCCTCC-3 '
Human decorin antisense primer 5'-GTCGCGGTCATCAGGAACTT-3 '
Human 36B4 sense primer 5'-ATGCAGCAGATCCGCATGT-3 '
Human 36B4 antisense primer 5'-TTGCGCATCATGGTGTTCTT-3 '
(Ii) Reaction conditions: 95 ° C, 1 minute, 1 cycle
95 ° C, 30 seconds → 60 ° C, 1 minute 40 cycles
95 ° C, 15 seconds → 60 ° C, 1 minute → 95 ° C, 15 seconds 1 cycle
反応終了後、36B4を内標準遺伝子としてデコリン遺伝子発現量を標準化した。使用したプライマーは以下の通りである。コントロールは発酵生成物を添加していないD−MEM培地で培養した細胞を使用し、各試料のデコリン遺伝子発現量をコントロールに対する相対量として算出した。この結果も表1に示す。なお、表中の数値は3ウエルの平均値である。 After completion of the reaction, the decorin gene expression level was normalized using 36B4 as an internal standard gene. The used primers are as follows. As a control, cells cultured in a D-MEM medium to which no fermentation product was added were used, and the decorin gene expression level of each sample was calculated as a relative amount to the control. The results are also shown in Table 1. In addition, the numerical value in a table | surface is an average value of 3 wells.
本試験および以下の試験において、目視での確認では、コントロール、1%、2%添加後の細胞数はほぼ同程度であったので、それぞれの細胞が発現ないし産生するデコリン量や、デルマトポンチン量が増えたと考えられる。なお、遺伝子発現量と培地中の産生量は一般的に相関する値であり、遺伝子発現量が増加した場合、培地中の産生量も増加することが本試験でも確認された。 In this test and the following tests, the number of cells after addition of control, 1%, and 2% was almost the same in visual confirmation. Therefore, the amount of decorin and dermatopontin expressed or produced by each cell were It is thought that it increased. The gene expression level and the production amount in the medium are generally correlated values, and it was also confirmed in this test that the gene production level increases when the gene expression level increases.
試 験 例 2
デコリン量の測定(2)
発酵生成物2を使用する以外は、試験例1と同様にして、デコリンの産生量および遺伝子発現量を調べた。なお、比較として、未発酵生成物(製造例2において、菌液接種のみを行わず、他は同一工程を経たもの)を使用した。この結果を表2に示す。Test example 2
Measurement of decorin (2)
Decorin production and gene expression were examined in the same manner as in Test Example 1 except that the fermentation product 2 was used. In addition, as a comparison, an unfermented product (in Production Example 2, only the bacterial solution inoculation was not performed and the others were subjected to the same process) was used. The results are shown in Table 2.
この結果、発酵生成物を用いた場合にはデコリンの産生量の増加が認められたが、未発酵生成物では、デコリンの産生量の増加は認められないことが示された。 As a result, it was shown that when the fermentation product was used, an increase in the production amount of decorin was recognized, but in the unfermented product, an increase in the production amount of decorin was not observed.
試 験 例 3
デコリン量の測定(3)
線維芽細胞を表皮角化細胞に変更する以外は、試験例2と同様にしてデコリン遺伝子の発現量を調べた。なお、比較としては、ブチレングリコールを使用した。この結果を表3に示す。Test example 3
Measurement of decorin (3)
The expression level of the decorin gene was examined in the same manner as in Test Example 2 except that the fibroblasts were changed to epidermal keratinocytes. For comparison, butylene glycol was used. The results are shown in Table 3.
試 験 例 4
デルマトポンチン量の測定
試験例1と同様にしてデルマトポンチンの遺伝子発現量を調べた。使用したプライマーは以下の通りである。この結果を表4に示す。Test example 4
Measurement of dermatopontin level In the same manner as in Test Example 1, the gene expression level of dermatopontin was examined. The used primers are as follows. The results are shown in Table 4.
(i)プライマー
ヒトデルマトポンチン センスプライマー 5’-TGGGTGAATTTGAACCGGCAA-3’
ヒトデルマトポンチン アンチセンスプライマー 5’-CGTAGTTCCATTGTCTGTCAGAA-3’(I) Primer human dermatopontin sense primer 5'-TGGGTGAATTTGAACCGGCAA-3 '
Human dermatopontin antisense primer 5'-CGTAGTTCCATTGTCTGTCAGAA-3 '
試 験 例 5
バーシカンの遺伝子発現量の測定
試験例1と同様にしてバーシカンの遺伝子発現量を調べた。使用したプライマーは以下の通りである。この結果を表5に示す。Test example 5
Measurement of Versican Gene Expression Level In the same manner as in Test Example 1, versican gene expression level was examined. The used primers are as follows. The results are shown in Table 5.
(i)プライマー
ヒトバーシカン センスプライマー 5’GTAACCCATGCGCTACATAAAGT--3’
ヒトバーシカン アンチセンスプライマー 5’-GGCAAAGTAGGCATCGTTGAAA-3’(I) Primer human versican sense primer 5'GTAACCCATGCGCTACATAAAGT- 3 '
Human versican antisense primer 5'-GGCAAAGTAGGCATCGTTGAAA-3 '
この結果から、本発明のコラーゲン増強剤は、バーシカンの量を増加させることはなく、また添加量が増えると、予想外にバーシカンの量を減少させることが確認された。 From these results, it was confirmed that the collagen enhancer of the present invention did not increase the amount of versican, and unexpectedly decreased the amount of versican as the amount added increased.
試 験 例 6
デコリン量の測定(4)
表皮角化細胞(NHEK)を使用する以外は、試験例1と同様にして、デコリンの遺伝子発現量を調べた。Test example 6
Measurement of decorin (4)
Decorin gene expression level was examined in the same manner as in Test Example 1 except that epidermal keratinocytes (NHEK) were used.
その結果、試験例1と同様に、コントロールと比較してデコリンの遺伝子発現量が増加することが確認された。 As a result, as in Test Example 1, it was confirmed that the gene expression level of decorin was increased as compared with the control.
試 験 例 7
3次元培養表皮モデル(表皮角化細胞)でのデコリンタンパクの発現
量の測定
ヒト3次元培養表皮モデル(Labcyte Epi-model 24(J−TEC製))を用いて発酵生成物の作用を評価した。まず、最終濃度が2または5%となるようにPBS緩衝液で希釈した発酵生成物2を角質層側に添加し、37℃で48時間培養した。コントロールとしては、発酵生成物を添加していないPBS緩衝液を使用し、同様に培養を行った。Test example 7
Measurement of the expression level of decorin protein in a three-dimensional cultured epidermis model (epidermal keratinocytes) The effect of fermentation products was evaluated using a human three-dimensional cultured epidermis model (Labcyte Epi-model 24 (manufactured by J-TEC)). . First, fermentation product 2 diluted with PBS buffer so that the final concentration was 2 or 5% was added to the stratum corneum side, and cultured at 37 ° C. for 48 hours. As a control, a PBS buffer solution to which no fermentation product was added was used, and culture was performed in the same manner.
培養後、試験例1に記載の方法でそれぞれの基底層側の培養上清中に産生されたデコリン量をウェスタンブロット法により測定した。この結果を、表6に示す。 After the culture, the amount of decorin produced in the culture supernatant of each basal layer side was measured by the method described in Test Example 1 by Western blotting. The results are shown in Table 6.
この結果、より皮膚の生理的条件に近い系においても発酵生成物2がデコリンの産生を促進することが確認された。この結果から、実際の皮膚組織や人工皮膚においても、本発明のコラーゲン増強剤を適用することにより、プロテオグリカン量が増加し、コラーゲン線維の結束能を増強することが示唆された。 As a result, it was confirmed that the fermentation product 2 promotes decorin production even in a system closer to the physiological condition of the skin. From these results, it was suggested that the amount of proteoglycan is increased and the binding ability of collagen fibers is enhanced by applying the collagen enhancer of the present invention also in actual skin tissue and artificial skin.
製 剤 例 1
乳液の調製:
表7に記載の組成で乳液を調製した。なお、乳液の調製は、9に6、7及び8を加えて加温し、80℃で1〜5を加えて乳化し、室温まで冷却することで行った。Product example 1
Emulsion preparation:
An emulsion was prepared with the composition described in Table 7. The emulsion was prepared by adding 6, 7 and 8 to 9 and heating, adding 1 to 5 at 80 ° C. to emulsify, and cooling to room temperature.
製 剤 例 2
クリームの調製:
表8に記載の組成でクリームを調製した。なお、クリームの調製は、10に7、8及び9を加えて加温し、80℃で1〜6を加えて乳化し、室温まで冷却することで行った。Product example 2
Cream preparation:
Creams were prepared with the compositions listed in Table 8. In addition, preparation of cream was performed by adding 7, 8, and 9 to 10 and heating, adding 1-6 at 80 degreeC, emulsifying, and cooling to room temperature.
製 剤 例 3
化粧水の調製:
表9に記載の組成で化粧水を調製した。なお、化粧水の調製は、8に1〜7を加えて十分に攪拌後、9を加えてpHを弱酸性に調整することで行った。Product example 3
Preparation of lotion:
A lotion was prepared with the composition shown in Table 9. The lotion was prepared by adding 1 to 7 to 8 and stirring sufficiently, and then adding 9 to adjust the pH to slightly acidic.
製 剤 例 4
乳液の調製:
表10に記載の組成で乳液を調製した。なお、乳液の調製は、13に1〜7を加えて加温し、80℃で8〜12を加えて乳化後、14及び15を加えた後に室温まで冷却し、16〜18を加えることで行った。Product example 4
Emulsion preparation:
An emulsion was prepared with the composition described in Table 10. The emulsion is prepared by adding 1 to 7 to 13 and heating, adding 8 to 12 at 80 ° C., emulsifying, adding 14 and 15, then cooling to room temperature, and adding 16 to 18. went.
製 剤 例 5
化粧水の調製:
発酵生成物3または4を使用する以外は、製剤例3に記載の方法で化粧水を調製した。Product example 5
Preparation of lotion:
A lotion was prepared by the method described in Formulation Example 3 except that fermentation product 3 or 4 was used.
製 剤 例 6
乳液の調製:
発酵生成物3または4を使用する以外は、製剤例4に記載の方法で乳液を調製した。Product example 6
Emulsion preparation:
An emulsion was prepared by the method described in Formulation Example 4 except that fermentation product 3 or 4 was used.
本発明のコラーゲン線維の結束能増強剤の有効成分である発酵生成物は、デコリン、デルマトポンチン等のプロテオグリカンの量を増やす作用があり、しかもこのプロテオグリカンは、コラーゲン線維束の形成を促進させて組織強度を増強させるものである。 The fermentation product, which is an active ingredient of the collagen fiber binding ability enhancer of the present invention, has the effect of increasing the amount of proteoglycan such as decorin and dermatopontin, and this proteoglycan promotes the formation of collagen fiber bundles to enhance tissue strength. Is to strengthen.
従って、本発明のコラーゲン線維の結束能増強剤は、これを、事故、疾病等により強度が低下した、靭帯、腱、軟骨、皮膚、歯周組織等の生体組織に使用することで、特定のプロテオグリカンの量を増やし、正常なコラーゲン組織に修復することができるものであり、医薬品、皮膚外用剤、化粧料等として利用できるものである。また、近年注目されている再生医療のために人工的に作られる組織の強度を上げるための添加剤としても利用することができる。 Therefore, the collagen fiber bundling ability enhancer of the present invention can be used in a specific tissue such as a ligament, tendon, cartilage, skin, periodontium, etc. whose strength has been reduced due to an accident, disease, etc. It can increase the amount of proteoglycan and restore it to normal collagen tissue, and can be used as a pharmaceutical, an external preparation for skin, a cosmetic, and the like. It can also be used as an additive for increasing the strength of artificially produced tissue for regenerative medicine, which has attracted attention in recent years.
Claims (8)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013177632 | 2013-08-29 | ||
JP2013177632 | 2013-08-29 | ||
PCT/JP2014/071994 WO2015029895A1 (en) | 2013-08-29 | 2014-08-22 | Bindability enhancer for collagen fibers |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2015029895A1 JPWO2015029895A1 (en) | 2017-03-02 |
JP6234465B2 true JP6234465B2 (en) | 2017-11-22 |
Family
ID=52586454
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015534177A Active JP6234465B2 (en) | 2013-08-29 | 2014-08-22 | Collagen fiber bundling ability enhancer |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP6234465B2 (en) |
TW (1) | TWI701033B (en) |
WO (1) | WO2015029895A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR106385A1 (en) * | 2015-10-15 | 2018-01-10 | Natura Cosmeticos Sa | COSMETIC COMPOSITION THAT INCLUDES PROBIOTIC BACTERIA |
JP7530750B2 (en) | 2020-06-10 | 2024-08-08 | 花王株式会社 | Gingival recession inhibitor |
CN116195742B (en) * | 2021-11-30 | 2024-07-09 | 内蒙古伊利实业集团股份有限公司 | Application of bifidobacterium lactis BL-99 in cartilage protection |
CN115089767B (en) * | 2022-05-25 | 2023-06-20 | 中山大学 | Soybean wound repair material and preparation method and application thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3129646B2 (en) * | 1996-01-19 | 2001-01-31 | 鐘紡株式会社 | Ceramide synthesis promoter |
EP1344528B1 (en) * | 2000-12-19 | 2008-10-08 | Kabushiki Kaisha Yakult Honsha | External skin preparations and process for producing the same |
JP4612183B2 (en) * | 2000-12-27 | 2011-01-12 | 株式会社ヤクルト本社 | External composition for skin and method for producing the same |
FR2834718B1 (en) * | 2002-01-15 | 2004-12-24 | Cognis France Sa | COSMETIC AND / OR PHARMACEUTICAL ACTIVE SUBSTANCES |
GB0605949D0 (en) * | 2006-03-24 | 2006-05-03 | Quest Int Serv Bv | Milk product for skin treatment |
JP5791009B2 (en) * | 2008-12-22 | 2015-10-07 | アサヒグループホールディングス株式会社 | Lactic acid bacteria and food or drink using them |
-
2014
- 2014-08-22 JP JP2015534177A patent/JP6234465B2/en active Active
- 2014-08-22 WO PCT/JP2014/071994 patent/WO2015029895A1/en active Application Filing
- 2014-08-28 TW TW103129698A patent/TWI701033B/en active
Also Published As
Publication number | Publication date |
---|---|
TW201521750A (en) | 2015-06-16 |
TWI701033B (en) | 2020-08-11 |
WO2015029895A1 (en) | 2015-03-05 |
JPWO2015029895A1 (en) | 2017-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100858575B1 (en) | External skin preparations and process for producing the same | |
JP4612180B2 (en) | Skin preparation | |
EP2057981A1 (en) | Anti-wrinkle agent | |
JP5528629B2 (en) | A polyphosphoric acid composition containing polyphosphoric acid extracted from yeast, a salt of polyphosphoric acid, or a solvate of polyphosphoric acid, and a method for producing the same. | |
JP6234465B2 (en) | Collagen fiber bundling ability enhancer | |
JP2015034131A (en) | Fermented fig extract, method for producing the same, and cosmetic in which fermented fig extract is blended | |
JP4512265B2 (en) | Lactic acid bacteria culture supernatant, method for producing the same, and external preparation for skin using the supernatant | |
JP4612183B2 (en) | External composition for skin and method for producing the same | |
TW201223559A (en) | Cytoprotective agent | |
JP6320867B2 (en) | Lactic acid fermented egg white-containing cosmetic and method for producing the same | |
CN115024997A (en) | Cosmetic composition with skin aging resisting effect | |
JP6805399B2 (en) | Skin care agent containing plant-derived lactic acid bacteria | |
JP6362836B2 (en) | emulsifier | |
JP2018048103A (en) | Skin quality improving agent | |
JP2009149557A (en) | Skin amelioration agent | |
JP2021172593A (en) | External preparation for skin | |
JP6792270B2 (en) | Whitening composition | |
KR101814537B1 (en) | A skin topical composition comprising the bio-cellulose powder for reducing and preventing cellulite | |
KR101814538B1 (en) | A cosmentic composition comprising the bio-cellulose powder for reducing and preventing cellulite | |
JP2007008911A (en) | Cosmetic | |
JP2007176832A (en) | Skin ageing-preventing composition containing extract of aphanizomenon | |
EP4385493A1 (en) | Cosmetic composition, use of casearia sylvestris, schinus terebinthifolius, hymenaea courbaril and lactobacillus, and method for preventing and or treating signs os skin ageing | |
JP5219429B2 (en) | Pregnancy line prevention and / or treatment agent | |
JP5527917B2 (en) | Arginase activity promoter and skin external preparation containing the same | |
JP2005206510A (en) | Hyaluronic acid production promoter and composition of external preparation for skin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170321 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170519 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170718 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20170718 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20171010 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20171024 |
|
R151 | Written notification of patent or utility model registration |
Ref document number: 6234465 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R151 |